@article{8daeaafcb9eb4c71a4010ece0e87fe8e,
title = "Association of Performance on the Financial Capacity Instrument-Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults",
abstract = "Background and ObjectivesTo investigate the association of the Financial Capacity Instrument-Short Form (FCI-SF) performance and timing total scores with brain β-amyloid and cortical thickness in cognitively unimpaired (CU) (at baseline) older adults.MethodsA total of 309 participants (aged 70 years or older) of the Mayo Clinic Study of Aging underwent 11C-Pittsburgh compound B PET amyloid imaging and MRI, and completed the FCI-SF. Abnormal amyloid PET was defined as standardized uptake value ratio ≥1.48 in an Alzheimer disease (AD)-related region of interest and reduced AD signature cortical thickness as ≤2.68 mm (neurodegeneration). A cohort of 218 (of the 309) participants had follow-up visits (every 15 months) with FCI-SF data for longitudinal analysis (number of visits including baseline, median [range]: 2 [2-4]). In the analysis, we used linear regression and mixed-effects models adjusted for age, sex, education, apolipoprotein E ϵ4 allele status, global cognitive z score, and previous FCI-SF testing.ResultsParticipants' mean age (SD) was 80.2 (4.8) years (56.3% male individuals). In cross-sectional analysis, abnormal amyloid PET (vs normal) was associated with a lower FCI-SF total score and slower total composite time. In longitudinal analysis, FCI-SF total score declined faster (difference in annualized rate of change, beta coefficient [β] [95% confidence interval (CI)] = -1.123 [-2.086 to -0.161]) and FCI-SF total composite time increased faster (difference in annualized rate of change, β [95% CI] = 16.274 [5.951 to 26.597]) for participants with neurodegeneration at baseline (vs those without). Participants who exhibited both abnormal amyloid PET and neurodegeneration at baseline had a greater increase in total composite time when compared with the group without abnormal amyloid and without neurodegeneration (difference in annualized rate of change, β [95% CI] = 16.750 [3.193 to 30.307]).DiscussionPerformance and processing speed on the FCI-SF were associated with imaging biomarkers of AD pathophysiology in CU (at baseline) older adults. Higher burdens of imaging biomarkers were associated with longitudinal worsening on FCI-SF performance. Additional research is needed to delineate further these associations and their predictive utility at the individual person level.",
author = "Maria Vassilaki and Aakre, {Jeremiah A.} and Kremers, {Walter K.} and Mielke, {Michelle M.} and Geda, {Yonas E.} and MacHulda, {Mary M.} and Knopman, {David S.} and Prashanthi Vemuri and Lowe, {Val J.} and Jack, {Clifford R.} and Roberson, {Erik D.} and Adam Gerstenecker and Martin, {Roy C.} and Kennedy, {Richard E.} and Marson, {Daniel C.} and Petersen, {Ronald C.}",
note = "Funding Information: M. Vassilaki has received research funding from F. Hoffmann-La Roche Ltd and Biogen in the past and consults for F. Hoffmann-La Roche Ltd; she, receives research funding from NIH and St. Anne{\textquoteright}s University Hospital Brno, International Clinical Research Center, Czech Republic/EU, and has equity ownership in Abbott Laboratories, Johnson and Johnson, Medtronic and Amgen. J.A. Aakre reports no disclosures. W.K. Kremers receives research funding from Department of Defense, NIH, Astra Zeneca, Biogen, and Roche. M.M. Mielke consults for Brain Protection Company and Biogen and receives research funding from the NIH/NIA. Y.E. Geda receives funding from NIH and Roche and previously served on Lundbeck Advisory Board. M.M. Machulda receives NIH funding. D.S. Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer's Treatment and Research Institute at USC; and receives research support from the NIH. P. Vemuri receives NIH funding. V.J. Lowe serves on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences, Merck Research, and AVID Radiopharmaceuticals and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA and NCI). C.R. Jack, Jr., serves on scientific advisory board for Eli Lilly & Company; receives research support from the NIH/NIA, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; and holds stock in Johnson & Johnson. E.D. Roberson serves on scientific advisory boards for Biogen, AGTC, and AVROBIO and receives funding from NIH, Bluefield Project, and Alzheimer's Drug Discovery Foundation. A. Gerstenecker receives NIH funding. R.C. Martin receives funding from NSF and NIH. R.E. Kennedy receives NIH funding. D.C. Marson receives NIH funding; is the inventor of the FCI-SF and the UAB Research Foundation (UABRF); owns the FCI-SF through copyright and trademark (FCAP); has previously received royalty and consulting income from UABRF licensed use and sale of the FCI-SF; and is currently a consultant on an unaffiliated NIH grant using the FCI-SF. R.C. Petersen is a consultant for Roche, Inc., Biogen, Inc., Merck, Inc., Eli Lilly and Company, and Genentech, Inc.; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and receives research support from the National Institute of Health. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp . Funding Information: The study was supported by the NIH (U01 AG006786, P50 AG016574, R01AG057708, R01 AG011378, R01 AG021927, R01 AG041851, and R01 NS097495), the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic, the Alice Weiner Postdoctoral Research Fellowship in Alzheimer's Disease Research, Mayo Foundation for Medical Education and Research, the Liston Award, the Schuler Foundation, and the Alice Weiner Postdoctoral Research Fellow in Alzheimer's Disease Research and was made possible by the Rochester Epidemiology Project (R01 AG034676). Publisher Copyright: {\textcopyright} American Academy of Neurology.",
year = "2022",
month = apr,
day = "1",
doi = "10.1212/CPJ.0000000000001157",
language = "English (US)",
volume = "12",
pages = "113--124",
journal = "Neurology: Clinical Practice",
issn = "2163-0402",
publisher = "Lippincott Williams and Wilkins",
number = "2",
}